Market Research Logo

Traveler's Diarrhea - Pipeline Review, H2 2016

Traveler's Diarrhea - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Traveler's Diarrhea - Pipeline Review, H2 2016’, provides an overview of the Traveler's Diarrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Traveler's Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traveler's Diarrhea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Traveler's Diarrhea
    • The report reviews pipeline therapeutics for Traveler's Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Traveler's Diarrhea therapeutics and enlists all their major and minor projects
    • The report assesses Traveler's Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Traveler's Diarrhea
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Traveler's Diarrhea
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Traveler's Diarrhea pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Traveler's Diarrhea Overview
    Therapeutics Development
    Pipeline Products for Traveler's Diarrhea - Overview
    Pipeline Products for Traveler's Diarrhea - Comparative Analysis
    Traveler's Diarrhea - Therapeutics under Development by Companies
    Traveler's Diarrhea - Therapeutics under Investigation by Universities/Institutes
    Traveler's Diarrhea - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Traveler's Diarrhea - Products under Development by Companies
    Traveler's Diarrhea - Products under Investigation by Universities/Institutes
    Traveler's Diarrhea - Companies Involved in Therapeutics Development
    Cosmo Pharmaceuticals NV
    GlaxoSmithKline Plc
    Nippon Shinyaku Co., Ltd.
    Prokarium Limited
    Scandinavian Biopharma Holding AB
    Sigmoid Pharma Limited
    Traveler's Diarrhea - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    Etvax - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GVXNSD-133 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMSUTMR-1501 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    prulifloxacin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rifamycin CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Typhetec - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Traveler's Diarrhea - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Traveler's Diarrhea - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Traveler's Diarrhea - Dormant Projects
    Traveler's Diarrhea - Discontinued Products
    Traveler's Diarrhea - Product Development Milestones
    Featured News & Press Releases
    Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX
    Oct 04, 2013: Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers’ Diarrhea
    Sep 11, 2012: Santarus Announces Positive Top-Line Phase III Results For Rifamycin SV MMX In Travelers' Diarrhea
    Sep 14, 2009: Data From Optimers Second Phase III Study of Prulifloxacin Presented At Annual Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC)
    Sep 02, 2009: Optimer Pharmaceuticals Announces Presentations Of Additional Phase III Prulifloxacin Data At Upcoming ICAAC Annual Meeting
    Feb 26, 2009: Optimer Pharmaceuticals Announces Publication In Peer-Reviewed Journal About Prulifloxacins Antibacterial Activity Against Infectious Diarrhea Producing Bacteria
    Feb 24, 2009: Optimer Pharmaceuticals Announces Positive Results From Second Phase III Study Of Prulifloxacin For Infectious Diarrhea In Travelers
    Oct 20, 2008: Data from Optimer Pharmaceuticals Prulifloxacin Phase III Trial In Travelers Diarrhea Presented At ICAAC/IDSA Annual Meeting
    Sep 02, 2008: Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase III Clinical Trial
    Jul 16, 2008: Optimer Pharmaceuticals Announces Positive Results In Prulifloxacin Phase III Study
    Mar 11, 2008: Optimer Pharmaceuticals Completes Enrollment In Phase III Clinical Trial Of Prulifloxacin In Patients with Travelers’ Diarrhea
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Traveler's Diarrhea, H2 2016
    Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Traveler's Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H2 2016
    Traveler's Diarrhea - Pipeline by GlaxoSmithKline Plc, H2 2016
    Traveler's Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
    Traveler's Diarrhea - Pipeline by Prokarium Limited, H2 2016
    Traveler's Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2016
    Traveler's Diarrhea - Pipeline by Sigmoid Pharma Limited, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Traveler's Diarrhea - Dormant Projects, H2 2016
    Traveler's Diarrhea - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Traveler's Diarrhea, H2 2016
    Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report